Sublobectomy Extends Survival in IDH-Wildtype Glioblastoma

The surgical management of glioblastoma focuses on maximizing the extent of resection while minimizing postoperative neurological morbidity [1]. Although achieving gross total resection of the contrast-enhancing tumor volume is a standard goal, the infiltrative nature of these high-grade gliomas often leads to recurrence within the surrounding brain tissue. Clinicians must navigate the tension between aggressive debulking and the preservation of eloquent cortical areas (regions of the brain responsible for critical functions like speech or movement) to maintain patient quality of life. A retrospective study of 331 patients with isocitrate dehydrogenase-wildtype glioblastoma evaluated sublobectomy, a standardized supramaximal resection technique that incorporates lobe-specific anatomical boundaries and functional mapping limits [1]. The researchers found that sublobectomy significantly improved median overall survival to 25.6 months compared to 18.1 months for standard contrast-enhancing resection (p < 0.001), with similar improvements in progression-free survival (17.0 vs 12.0 months, p < 0.001) [1]. Functional assessments indicated that this more extensive resection did not increase risks to language function or physical performance, offering a viable strategy to extend survival without sacrificing functional independence [1].